First-line treatment of patients with chronic-phase chronic myelogenous leukemia: Progress and remaining questions

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Imatinib is the standard first-line therapy for chronic-phase chronic myelogenous leukemia (CP CML). However, only 57% of patients in the key IRIS (International Randomized Study of Interferon and STI571) study now remain on imatinib per protocol with complete cytogenetic response (CCyR), and the lost follow-up on off-protocol patients precludes accurately determining efficacy and long-term survival. The UK front-line study, an intent-to-treat analysis of patients with newly diagnosed CP CML, supports the data generated by IRIS, with follow-up data available for all enrollees. This study suggests that patients who fail to achieve hematologic and cytogenetic responses by specified timepoints have inferior progression-free and overall survival and are thus intriguing targets for therapeutic intervention. This review discusses the results of the UK and other studies and evaluates available second-line treatment options for patients with CP CML.

Original languageEnglish (US)
Pages (from-to)160-165
Number of pages6
JournalCommunity Oncology
Volume7
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Interferons
Therapeutics
Disease-Free Survival
Survival
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

First-line treatment of patients with chronic-phase chronic myelogenous leukemia : Progress and remaining questions. / DeVetten, Marcel P.

In: Community Oncology, Vol. 7, No. 4, 04.2010, p. 160-165.

Research output: Contribution to journalReview article

@article{f4f6b2eb2cf4434d9890c2fbce7cb827,
title = "First-line treatment of patients with chronic-phase chronic myelogenous leukemia: Progress and remaining questions",
abstract = "Imatinib is the standard first-line therapy for chronic-phase chronic myelogenous leukemia (CP CML). However, only 57{\%} of patients in the key IRIS (International Randomized Study of Interferon and STI571) study now remain on imatinib per protocol with complete cytogenetic response (CCyR), and the lost follow-up on off-protocol patients precludes accurately determining efficacy and long-term survival. The UK front-line study, an intent-to-treat analysis of patients with newly diagnosed CP CML, supports the data generated by IRIS, with follow-up data available for all enrollees. This study suggests that patients who fail to achieve hematologic and cytogenetic responses by specified timepoints have inferior progression-free and overall survival and are thus intriguing targets for therapeutic intervention. This review discusses the results of the UK and other studies and evaluates available second-line treatment options for patients with CP CML.",
author = "DeVetten, {Marcel P}",
year = "2010",
month = "4",
doi = "10.1016/S1548-5315(11)70295-9",
language = "English (US)",
volume = "7",
pages = "160--165",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "4",

}

TY - JOUR

T1 - First-line treatment of patients with chronic-phase chronic myelogenous leukemia

T2 - Progress and remaining questions

AU - DeVetten, Marcel P

PY - 2010/4

Y1 - 2010/4

N2 - Imatinib is the standard first-line therapy for chronic-phase chronic myelogenous leukemia (CP CML). However, only 57% of patients in the key IRIS (International Randomized Study of Interferon and STI571) study now remain on imatinib per protocol with complete cytogenetic response (CCyR), and the lost follow-up on off-protocol patients precludes accurately determining efficacy and long-term survival. The UK front-line study, an intent-to-treat analysis of patients with newly diagnosed CP CML, supports the data generated by IRIS, with follow-up data available for all enrollees. This study suggests that patients who fail to achieve hematologic and cytogenetic responses by specified timepoints have inferior progression-free and overall survival and are thus intriguing targets for therapeutic intervention. This review discusses the results of the UK and other studies and evaluates available second-line treatment options for patients with CP CML.

AB - Imatinib is the standard first-line therapy for chronic-phase chronic myelogenous leukemia (CP CML). However, only 57% of patients in the key IRIS (International Randomized Study of Interferon and STI571) study now remain on imatinib per protocol with complete cytogenetic response (CCyR), and the lost follow-up on off-protocol patients precludes accurately determining efficacy and long-term survival. The UK front-line study, an intent-to-treat analysis of patients with newly diagnosed CP CML, supports the data generated by IRIS, with follow-up data available for all enrollees. This study suggests that patients who fail to achieve hematologic and cytogenetic responses by specified timepoints have inferior progression-free and overall survival and are thus intriguing targets for therapeutic intervention. This review discusses the results of the UK and other studies and evaluates available second-line treatment options for patients with CP CML.

UR - http://www.scopus.com/inward/record.url?scp=77952909399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952909399&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70295-9

DO - 10.1016/S1548-5315(11)70295-9

M3 - Review article

AN - SCOPUS:77952909399

VL - 7

SP - 160

EP - 165

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 4

ER -